Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus ATRIDOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus ATRIDOX.
ACHROMYCIN vs ATRIDOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic